Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ZEALAND PHARMA US, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Coverage of anti-obesity medications under Medicare and Medicaid.
ONE WORLD TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Source: Senate LDA
| BIOHAVEN PHARMACEUTICALS, INC. |
| 12 |
| 2022–2025 |
| ILLUMINA, INC. | 10 | 2021–2023 |
| ResMed Corp. | 10 | 2022–2025 |
| ACXIOM LLC | 9 | 2021–2022 |
| ST. GEORGES UNIVERSITY | 8 | 2021–2022 |
| XEROX HOLDINGS CORPORATION (FORMERLY LEXMARK INTERNATIONAL, INC.) | 8 | 2025–2026 |
| BIONJ, INC. | 7 | 2025–2026 |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 7 | 2025–2026 |
| GENENTECH USA, INC. | 7 | 2021–2022 |
| SAB BIOTHERAPEUTICS, INC. | 6 | 2021–2022 |
| IMMUNOCORE, LLC | 5 | 2022–2023 |
| CALIFORNIA APARTMENT ASSOCIATION | 4 | 2025 |
| CORVENT MEDICAL, INC. | 4 | 2026 |
| SAMSUNG SDI AMERICA, INC | 4 | 2024–2025 |
| ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) | 3 | 2026 |
| FLIPT, LLC | 3 | 2021 |
| GLOBAL PLASMA SOLUTIONS INC. | 3 | 2021 |
| IRHYTHM TECHNOLOGIES INC | 3 | 2025 |
| ONE WORLD TECHNOLOGIES, INC. | 2 | 2026 |
| ST. JOSEPHS/CANDLER HEALTH SYSTEM, INC. | 2 | 2026 |
| ZEALAND PHARMA US, INC. | 2 | 2026 |
| NOVARTIS | 1 | 2025 |
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Treat and Reduce Obesity Act of 2025
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Treat and Reduce Obesity Act of 2025
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Treat and Reduce Obesity Act of 2025
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Treat and Reduce Obesity Act of 2025
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BIONJ, INC. · Firm: DLA PIPER LLP (US)
Public policy matters impacting the life sciences industry. H.R. 1, One Big Beautiful Bill Act, tax and healthcare provisions.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BIONJ, INC. · Firm: DLA PIPER LLP (US)
Public policy matters impacting the life sciences industry. H.R. 1, One Big Beautiful Bill Act, tax and healthcare provisions.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Mikaela Naylon Give Kids a Chance Act
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Department of Defense Appropriations Act, 2026
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4016, Department of Defense Appropriations Act for FY2026, provisions on data analytics.
Department of Defense Appropriations Act, 2026
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on data analytics.
Department of Defense Appropriations Act, 2026
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on data analytics.
Treat and Reduce Obesity Act of 2025
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Treat and Reduce Obesity Act of 2025
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Patients’ Right to Know Their Medication Act of 2025
Client: XEROX HOLDINGS CORPORATION · Firm: DLA PIPER LLP (US)
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Impacts and Outcomes for Health Career Training Act
Client: INTRA-CELLULAR THERAPIES, INC. · Firm: DLA PIPER LLP (US)
Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health. H.R. 5376, Impacts and Outcomes for Health Career Training Act.
Impacts and Outcomes for Health Career Training Act
Client: INTRA-CELLULAR THERAPIES, INC. · Firm: DLA PIPER LLP (US)
Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health. H.R. 5376, Impacts and Outcomes for Health Career Training Act.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Treat and Reduce Obesity Act of 2025
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Treat and Reduce Obesity Act of 2025
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Department of Defense Appropriations Act, 2026
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on data analytics.
Department of Defense Appropriations Act, 2026
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on data analytics.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Give Kids a Chance Act of 2025
Client: BIOTECHNOLOGY INNOVATION ORGANIZATION · Firm: DLA PIPER LLP (US)
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Treat and Reduce Obesity Act of 2023
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023. Article 20 pharmacovigilance proceedings before the European Commission.
Treat and Reduce Obesity Act of 2023
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Treat and Reduce Obesity Act of 2023
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023. Article 20 pharmacovigilance proceedings before the European Commission.
Treat and Reduce Obesity Act of 2023
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes.
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
Government contracting issues. H.R. 5894/S. 2624, Labor/HHS/Education Appropriations Act, FY2024, support for data-driven products and services. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services.
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029/S. 4942, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services. H.R. 8333, BIOSECURE Act.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029/S. 4942, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services. H.R. 8333, BIOSECURE Act.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029/S. 4942, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services.
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023. Article 20 pharmacovigilance proceedings before the European Commission.
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023. Article 20 pharmacovigilance proceedings before the European Commission.
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
Government contracting issues. H.R. 5894/S. 2624, Labor/HHS/Education Appropriations Act, FY2024, support for data-driven products and services. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029/S. 4942, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029/S. 4942, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services. H.R. 8333, BIOSECURE Act.
Department of Defense Appropriations Act, 2024
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4365, Department of Defense Appropriations, FY2024, support for data-driven products and services. Government contracting issues. Labor/HHS/Education Appropriations, FY2024, support for data-driven products and services. Reauthorization of the Pandemic and All Hazards Preparedness Act.
Department of Defense Appropriations Act, 2024
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4365, Department of Defense Appropriations, FY2024, support for data-driven products and services. Government contracting issues. H.R. 5894, Labor/HHS/Education Appropriations, FY2024, support for data-driven products and services. Reauthorization of the Pandemic and All Hazards Preparedness Act.
Department of Defense Appropriations Act, 2024
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4365/S. 2587, Department of Defense Appropriations, FY2024, support for data-driven products and services. Government contracting issues. H.R. 5894/S. 2624, Labor/HHS/Education Appropriations, FY2024, support for data-driven products and services. Reauthorization of the Pandemic and All Hazards Preparedness Act.
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Treat and Reduce Obesity Act of 2023
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Treat and Reduce Obesity Act of 2023
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Treat and Reduce Obesity Act of 2023
Client: CURRAX PHARMACEUTICALS LLC · Firm: DLA PIPER LLP (US)
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes.
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4365/S. 2587, Department of Defense Appropriations, FY2024, support for data-driven products and services. Government contracting issues. H.R. 5894/S. 2624, Labor/HHS/Education Appropriations, FY2024, support for data-driven products and services. Reauthorization of the Pandemic and All Hazards Preparedness Act.
Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes.
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4365, Department of Defense Appropriations, FY2024, support for data-driven products and services. Government contracting issues. H.R. 5894, Labor/HHS/Education Appropriations, FY2024, support for data-driven products and services. Reauthorization of the Pandemic and All Hazards Preparedness Act.
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. H.R. 4408/S. 1906, Promising Pathway Act.
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023.
Department of Defense Appropriations Act, 2024
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4365/S. 2587, Department of Defense Appropriations, FY2024, support for data-driven products and services. Government contracting issues. H.R. 5894/S. 2624, Labor/HHS/Education Appropriations, FY2024, support for data-driven products and services. Reauthorization of the Pandemic and All Hazards Preparedness Act.
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2024
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 4365/S. 2587, Department of Defense Appropriations, FY2024, support for data-driven products and services. Government contracting issues. H.R. 5894/S. 2624, Labor/HHS/Education Appropriations, FY2024, support for data-driven products and services. Reauthorization of the Pandemic and All Hazards Preparedness Act.
Ensuring Parity in MA and PACE for Audio-Only Telehealth Act of 2021
Client: INDEPENDENCE BLUE CROSS, LLC · Firm: DLA PIPER LLP (US)
Legislative proposals that impact the health insurance market. Medicare Advantage issues. H.R. 2166, Ensuring Parity in MA and PACE for Audio-Only Telehealth Act.
Government use of advanced analytics technology and regulation of personal information. State and Foreign Operations Appropriations, FY2023, funding for mental health research. MILCON-VA Appropriations, FY2023, funding for mental health research. H.R. 2471, Consolidated Appropriations Act, FY2022, funding for mental health.
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders. Legislative proposals to respond to the coronavirus pandemic. H.R. 5376, Inflation Reduction Act of 2022, Medicaid provisions.
Legislative and regulatory policies affecting biotechnology including: pharmaceutical development, approval reimbursement, and pricing; patient assistance and access programs; and benefit redesign. H.R. 5376, Build Back Better Act, drug pricing provisions. Labor/HHS/Education Appropriations for FY2023, provisions regarding pandemic response. CMS National Coverage Determination for Alzheimer's treatment. Potential pilot program combatting influenza.
Legislative and regulatory policies affecting biotechnology including: pharmaceutical development; biodefense; and diagnostics. H.R. 8295, Labor/HHS/Education Appropriations for FY2023, provisions regarding pandemic response. H.R. 5801, HELP Copays Act.
Legislative and regulatory policies affecting biotechnology including: pharmaceutical development; biodefense; and diagnostics. H.R. 8295, Labor/HHS/Education Appropriations for FY2023, provisions regarding pandemic response. H.R. 5801, HELP Copays Act.
Legislative and regulatory policies affecting biotechnology including: pharmaceutical development; biodefense; and diagnostics. H.R. 8295, Labor/HHS/Education Appropriations for FY2023, provisions regarding pandemic response. H.R. 5801, HELP Copays Act.
Department of Defense Appropriations Act, 2023
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 8236, Department of Defense Appropriations, FY2023, support for data-driven products and services. Government contracting issues. S. 3904, Healthcare Cybersecurity Act of 2022.
Department of Defense Appropriations Act, 2023
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 8236, Department of Defense Appropriations, FY2023, support for data-driven products and services.
Department of Defense Appropriations Act, 2023
Client: IQVIA HOLDINGS, INC. · Firm: DLA PIPER LLP (US)
H.R. 8236, Department of Defense Appropriations, FY2023, support for data-driven products and services.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023
Client: ACXIOM LLC · Firm: DLA PIPER LLP (US)
Government use of advanced analytics technology and regulation of personal information. H.R. 8282, State and Foreign Operations Appropriations, FY2023, funding for mental health research. H.R. 8238, MILCON-VA Appropriations, FY2023, funding for mental health research.
Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2023
Client: ACXIOM LLC · Firm: DLA PIPER LLP (US)
Government use of advanced analytics technology and regulation of personal information. H.R. 8282, State and Foreign Operations Appropriations, FY2023, funding for mental health research. H.R. 8238, MILCON-VA Appropriations, FY2023, funding for mental health research.
Department of State, Foreign Operations, and Related Programs Appropriations Act, 2023
Client: ACXIOM LLC · Firm: DLA PIPER LLP (US)
Government use of advanced analytics technology and regulation of personal information. H.R. 8282, State and Foreign Operations Appropriations, FY2023, funding for mental health research. H.R. 8238, MILCON-VA Appropriations, FY2023, funding for mental health research.
Proposed regulations regarding consumer products. Consumer Product Safety Commission issues.
Filing targets: Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, SENATE
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ST. JOSEPHS/CANDLER HEALTH SYSTEM, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Tax policy, Medicare wage index rates, and rural health incentives.
Tax policy, Medicare wage index rates, and rural health incentives.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIONJ, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Public policy matters impacting the life sciences industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERIHEALTH CARITAS via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders, and Medicaid and Medicare proposals and provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies related to life science industry and clinical trial reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · third_quarter · Q3
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
ST. JOSEPHS/CANDLER HEALTH SYSTEM, INC. via DLA PIPER LLP (US)
2026 · third_quarter · RR
Tax policy, Medicare wage index rates, and rural health incentives.
Tax policy, Medicare wage index rates, and rural health incentives.
ZEALAND PHARMA US, INC. via DLA PIPER LLP (US)
2026 · third_quarter · RR
Coverage of anti-obesity medications under Medicare and Medicaid.
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Policies related to life science industry and clinical trial reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ONE WORLD TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Proposed regulations regarding consumer products. Consumer Product Safety Commission issues.
Filing targets: Consumer Product Safety Commission (CPSC), Executive Office of the President (EOP), SENATE
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERIHEALTH CARITAS via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders, and Medicaid and Medicare proposals and provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIONJ, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Public policy matters impacting the life sciences industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals and policies regarding medical device coverage and reimbursement policies.
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues. IRA implementation.
340B drug discount program. General issues related to health care. Issues related to FDA drug review, including PDUFA.
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2026 · second_quarter · Q2
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCED MEDICAL TECHNOLOGY ASSOCIATION (ADVAMED) via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals and policies regarding medical device innovation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Policies related to life science industry and clinical trial reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIONJ, INC. via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Public policy matters impacting the life sciences industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERIHEALTH CARITAS via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders, and Medicaid and Medicare proposals and provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CORVENT MEDICAL, INC. via DLA PIPER LLP (US)
2026 · first_quarter · RR
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
Legislative and regulatory proposals, policies, and appropriations regarding ventilators and remote patient monitoring, federal ventilator stockpiling, and domestic manufacturing.
BIONJ, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Public policy matters impacting the life sciences industry.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on data analytics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTRA-CELLULAR THERAPIES, INC. via DLA PIPER LLP (US)
2025 · fourth_quarter · 4T
Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health. H.R. 5376, Impacts and Outcomes for Health Career Training Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA APARTMENT ASSOCIATION via DLA PIPER LLP (US)
2025 · fourth_quarter · 4T
Issues regarding the Veterans Health Care Act of 1992.
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERIHEALTH CARITAS via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders, and Medicaid and Medicare proposals and provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
AMERIHEALTH CARITAS via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders, and Medicaid and Medicare proposals and provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2025 · third_quarter · Q3
H.R. 4016/S. 2572, Department of Defense Appropriations Act for FY2026, provisions on data analytics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA APARTMENT ASSOCIATION via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Issues regarding the Veterans Health Care Act of 1992.
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
IRHYTHM TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to Medicare physician fee schedule.
Filing targets: SENATE
BIONJ, INC. via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Public policy matters impacting the life sciences industry. H.R. 1, One Big Beautiful Bill Act, tax and healthcare provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Ensuring full patient access to drug label and package insert information. H.R. 5133, Patients Right to Know Their Medication Act of 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTRA-CELLULAR THERAPIES, INC. via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health. H.R. 5376, Impacts and Outcomes for Health Career Training Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via DLA PIPER LLP (US)
2025 · third_quarter · 3T
Issues related to medical devices and healthcare policy. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2025 · second_quarter · 2A
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
H.R. 4016, Department of Defense Appropriations Act for FY2026, provisions on data analytics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTRA-CELLULAR THERAPIES, INC. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health.
Filing targets: HOUSE OF REPRESENTATIVES
CALIFORNIA APARTMENT ASSOCIATION via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Issues regarding the Veterans Health Care Act of 1992.
AMERIHEALTH CARITAS via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders, and Medicaid and Medicare proposals and provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIONJ, INC. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Public policy matters impacting the life sciences industry. H.R. 1, One Big Beautiful Bill Act, tax and healthcare provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Ensuring full patient access to drug label and package insert information.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Issues related to medical devices and healthcare policy. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IRHYTHM TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to Medicare physician fee schedule.
Filing targets: SENATE
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. H.R. 946, ORPHAN Cures Act. H.R. 1262/S. 932, The Give Kids a Chance Act. IRA implementation. 340B. Orphan drugs. Supply chain. Vaccine policy.
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2025 · second_quarter · Q2
Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CALIFORNIA APARTMENT ASSOCIATION via DLA PIPER LLP (US)
2025 · second_quarter · RR
Issues regarding the Veterans Health Care Act of 1992.
BIONJ, INC. via DLA PIPER LLP (US)
2025 · second_quarter · RR
Public policy matters impacting the life sciences industry.
NOVARTIS via DLA PIPER LLP (US)
2025 · second_quarter · RR
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
Federal proposals and policies impacting disease treatment, including: health care policies; Medicare and Medicaid payment, coverage, and reimbursement; drug pricing and supply chain issues; FDA policies and procedures; drug patents and patent reporting requirements; tariffs; tax reform and tax policy; and intellectual property protections and enforcement.
BIOTECHNOLOGY INNOVATION ORGANIZATION via DLA PIPER LLP (US)
2025 · second_quarter · RR
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
RESMED CORP. via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Issues related to medical devices and healthcare policy. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAMSUNG SDI AMERICA, INC via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Policies related to electric vehicles and battery electrification and manufacturing. Implementation of the Inflation Reduction Act of 2022, Pub. L. No. 117-169, provisions related to electric batteries.
Policies related to electric vehicles and battery electrification and manufacturing. Implementation of the Inflation Reduction Act of 2022, Pub. L. No. 117-169, provisions related to electric batteries.
Policies related to electric vehicles and battery electrification and manufacturing. Implementation of the Inflation Reduction Act of 2022, Pub. L. No. 117-169, provisions related to electric batteries and renewable tax credits.
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Ensuring full patient access to drug label and package insert information.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Legislative and regulatory policies and proposals related to obesity treatment. Article 20 pharmacovigilance proceedings before the European Commission.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IRHYTHM TECHNOLOGIES, INC. via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to Medicare physician fee schedule. Issues related to COVID-19.
Filing targets: SENATE
AMERIHEALTH CARITAS via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders, and Medicaid and Medicare proposals and provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENCE BLUE CROSS, LLC via DLA PIPER LLP (US)
2025 · first_quarter · 1T
Legislative proposals that impact the health insurance market. Medicare Advantage issues. Public payer reimbursement policies. Issues related to TRICARE competitive plan demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOHAVEN PHARMACEUTICALS, INC. via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTRA-CELLULAR THERAPIES, INC. via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2025 · first_quarter · Q1
Defense appropriations, data analytics and anti-trust policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
XEROX HOLDINGS CORPORATION via DLA PIPER LLP (US)
2025 · first_quarter · RR
Ensuring full patient access to drug label and package insert information.
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2024 · second_quarter · 2A
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Issues related to medical devices and healthcare policy. Supply chain issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029/S. 4942, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services. H.R. 8333, BIOSECURE Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023. Article 20 pharmacovigilance proceedings before the European Commission.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERIHEALTH CARITAS via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders, and Medicaid and Medicare proposals and provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENCE BLUE CROSS, LLC via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Legislative proposals that impact the health insurance market. Medicare Advantage issues. Public payer reimbursement policies. Issues related to TRICARE competitive plan demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTRA-CELLULAR THERAPIES, INC. via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOHAVEN PHARMACEUTICALS, INC. via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAMSUNG SDI AMERICA, INC via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Policies related to electric vehicles and battery electrification and manufacturing. Implementation of the Inflation Reduction Act of 2022, Pub. L. No. 117-169, provisions related to electric batteries. H.R. Res. 148, Congressional Review Act Resolution of Disapproval of the Dept. of the Treasury rule relating to "Clean Vehicle Credits Under Sections 25E and 30D" of the Inflation Reduction Act of 2022.
Policies related to electric vehicles and battery electrification and manufacturing. Implementation of the Inflation Reduction Act of 2022, Pub. L. No. 117-169, provisions related to electric batteries and renewable tax credits.
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2024 · fourth_quarter · Q4
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RESMED CORP. via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Issues related to medical devices and healthcare policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INDEPENDENCE BLUE CROSS, LLC via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Legislative proposals that impact the health insurance market. Medicare Advantage issues. Public payer reimbursement policies. Issues related to TRICARE competitive plan demonstration.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMERIHEALTH CARITAS via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Legislative and regulatory proposals affecting Medicaid Managed Care organizations. Medicaid extenders, and Medicaid and Medicare proposals and provisions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOHAVEN PHARMACEUTICALS, INC. via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Policies related to drug approval for treatment of rare diseases. Policies related to exclusivity of small molecule drugs. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
INTRA-CELLULAR THERAPIES, INC. via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Issues related to drug pricing, Medicare reimbursement, implementation of the Inflation Reduction Act, and mental health.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
B. BRAUN MEDICAL INC. via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Health care and budget related issues and congressional proposals affecting medical devices.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CURRAX PHARMACEUTICALS LLC via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Legislative and regulatory policies and proposals related to obesity treatment, including H.R. 4818/S. 2408, the Treat and Reduce Obesity Act of 2023. Article 20 pharmacovigilance proceedings before the European Commission.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SAMSUNG SDI AMERICA, INC via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Policies related to electric vehicles and battery electrification and manufacturing. Implementation of the Inflation Reduction Act of 2022, Pub. L. No. 117-169, provisions related to electric batteries and renewable tax credits.
Policies related to electric vehicles and battery electrification and manufacturing. Implementation of the Inflation Reduction Act of 2022, Pub. L. No. 117-169, provisions related to electric batteries. H.R. Res. 148, Congressional Review Act Resolution of Disapproval of the Dept. of the Treasury rule relating to "Clean Vehicle Credits Under Sections 25E and 30D" of the Inflation Reduction Act of 2022.
IQVIA HOLDINGS, INC. via DLA PIPER LLP (US)
2024 · third_quarter · Q3
Government contracting issues. Reauthorization of the Pandemic and All Hazards Preparedness Act. Data privacy proposals. H.R. 9029/S. 4942, Labor/HHS/Education Appropriations, FY2025, support for data-driven products and services.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to PAHPA reauthorization. Rare Pediatric Disease Priority Review Voucher Program reauthorization. Issues related to drug pricing and value generally. Issues related to pharmacy benefit managers and reporting requirements. 340B. Orphan drugs. Supply chain. Vaccine policy. Issues related to FDA, drug development, and clinical trial requirements.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to reimbursement under Medicare Part B and Part D. Medicare and Medicaid payment and coverage issues.
340B drug discount program. General issues related to health care. H.R. 946, ORPHAN Cures Act. Issues related to FDA drug review, including PDUFA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
Federal proposals and policies impacting the innovative biotechnology industry, including: health care policies; Medicare payment, coverage, and reimbursement; drug pricing and supply chain issues; and the reauthorization of the Pandemic and All Hazards Preparedness Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies related to electric vehicles and battery electrification and manufacturing. Implementation of the Inflation Reduction Act of 2022, Pub. L. No. 117-169, provisions related to electric batteries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Policies related to electric vehicles and battery electrification and manufacturing. Implementation of the Inflation Reduction Act of 2022, Pub. L. No. 117-169, provisions related to electric batteries.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE